eFFECTOR Therapeutics, Inc. Warrant
EFTRW
EFTRW was delisted on the 2nd of July, 2024.
12 hedge funds and large institutions have $290K invested in eFFECTOR Therapeutics, Inc. Warrant in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 0 closing their positions.
20% more funds holding
Funds holding: 10 → 12 (+2)
12% more capital invested
Capital invested by funds: $258K → $290K (+$31.5K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$192 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$136 |
| 2 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
-$13 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
1
Aristeia Capital
Greenwich,
Connecticut
| $158K | -$13 | -100 | -0% |
|
2
Goldman Sachs
New York
| $45.5K | – | – | – |
|
|
WA
3
Whitebox Advisors
Minneapolis,
Minnesota
| $44K | – | – | – |
|
|
MI
4
MMCAP International
Grand Cayman,
Cayman Islands
| $21.5K | – | – | – |
|
|
TCM
5
Tenor Capital Management
New York
| $4.92K | – | – | – |
|
|
PA
6
Parallel Advisors
San Francisco,
California
| $4.63K | – | – | – |
|
|
ICM
7
III Capital Management
Boca Raton,
Florida
| $4.43K | – | – | – |
|
|
SOA
8
Sea Otter Advisors
Miami,
Florida
| $3.69K | – | – | – |
|
|
WAM
9
Wolverine Asset Management
Chicago,
Illinois
| $2.6K | -$136 | -1,017 | -5% |
|
|
10
UBS Group
Zurich,
Switzerland
| $103 | +$192 | +1,434 | New |
|
|
TRCT
11
Tower Research Capital (TRC)
New York
| $2 | – | – | – |
|
|
PA
12
Pineridge Advisors
St. Charles,
Missouri
| $2 | +$4 | +33 | New |
|
EFTRW Hedge Fund Activity: Q4 2023 in Review
12 of the 6,863 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Warrant (EFTRW) for Q4 2023, worth a combined $290K — up 12% from $258K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new EFTRW positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $192. The largest seller was Wolverine Asset Management, cutting an estimated $136.
- 12 institutional investors held eFFECTOR Therapeutics, Inc. Warrant (EFTRW) as of Q4 2023, up from 10 in Q3 2023.
- Funds reported $290K of eFFECTOR Therapeutics, Inc. Warrant stock for Q4 2023, up 12% quarter-over-quarter.
- 2 funds opened new eFFECTOR Therapeutics, Inc. Warrant positions in Q4 2023 and 0 closed out, a net change of +2 holders.
- The largest eFFECTOR Therapeutics, Inc. Warrant buyer in Q4 2023 was UBS Group, an estimated $192 added.
- The largest eFFECTOR Therapeutics, Inc. Warrant seller in Q4 2023 was Wolverine Asset Management, an estimated $136 sold.
Based on aggregated 13F filings for Q4 2023.